Journal of Diabetes and Clinical Research

While the global COVID-19 pandemic has challenged the entire humanity and health systems, it also triggered researchers to urgently perform clinical trials to assess the safety and efficacy of many agents and modalities to combat COVID-19. As of April 22, over 650 clinical studies have been registered both in USA and internationally. Results from these studies are also coming at a brisk pace in this unprecedented emergency.

Ketamine has long been used in the field of anesthesia [1]. Its rapid and long-acting analgesic effects associated with its dissociative properties have also established its use in prehospital and emergency department patients.

The currently ongoing coronavirus pandemic, the SARSCOV- 2, interchangeably referred to as the COVID-19 infection, has in a short span of time altered the ways and means of almost all of mankind. So strong has been its effect that all human activity ceased in one way or another for a considerable time, led to significant loss of life and economic drain of.

There are many exciting developments in the field of midlife women’s health which explain how menopause symptoms, particularly hot flashes, may be an important vital sign and predictor of future health status. Additionally, in the therapeutic realm, there is a new class of medications that affect the thermoregulatory channels in the brain that control vasomotor symptoms (VMS). This development may unlock treatment options for women who cannot tolerate or cannot safely take hormone therapy.

Five months into the COVID-19 pandemic, the U.S. death toll from the virus has now surpassed 100,000 people. Many more cases remain nationwide, while an unknown number of patients currently harbor the virus asymptomatically. While health officials are now optimistic regarding the decline in prevalence and number of deaths due to COVID-19 and the possibility of a vaccine by the fall, we cannot lose sight of the bigger picture: the next pandemic.

Our modern world is facing extraordinary circumstances while passing through a serious pandemic caused by the novel coronavirus (COVID-19) which may lead to multi-organ system failure & death. Bcell depletion could compromise antiviral immunity, which makes the safety of rituximab use in the COVID19 era unclear.

In the article, “Mental Health Framework: Coronavirus pandemic in post-Katrina New Orleans” [1], Shervington and Richardson offer recommendations about how to anticipate and address disaster-related, trauma exposures associated with the coronavirus pandemic

In January 2020, the World Health Organization (WHO) classified COVID-19 to be a Public Health Emergency of International Concern and declared it a pandemic on March 11, 2020 [1]. Over one hundred and eighty-five million people have been infected by SARS-CoV-2 and roughly four million have died worldwide so far

Wound healing is a dynamic process whereby cellular structures and the tissue layers are reconstructed. Adult wound healing can be categorized into three stages: inflammatory phase, proliferative phase, and remodelling phase. Blood cells like macrophages, neutrophils, extracellular matrix and mediators, various proteins, and various genes play an important role in these phases.

However, the entire coagulation cascade is dysfunctional, in progressed chronic diabetes and cancer patients. Platelets (PLTs) in type 2 diabetic (DT2) involved in Thrombosis and Haemostasis (T&H) of individuals adhere to vascular endothelium and aggregate more voluntarily than those in healthy individuals, as are abnormalities in the microvascular and macrovascular circulations. However it is already known that the circulating PLTs are essential for T&H, inflammation growth factors delivery, regeneration; and knowledge of their function is fundamental to understanding the pathophysiology of vascular disease in diabetes and cancer-related diseases.

The COVID-19 pandemic has provoked a global, rapid increase of cases due to the high infectivity of the etiological agent, COVID-19 virus. In February 2021, over 110 million confirmed COVID-19 cases with 1 million deaths were reported worldwide (www.who.int).

In South Africa, new amended regulations required a review of complementary and alternative medicine (CAMs) call-up for registration from November 2013. This impacted traditional healers (THs)’ compliance with the regulatory authorities’ on the good manufacturing practice which in return affected the public’s access to CAMs. This investigation embraces methods, THs use to diagnose and treat diabetes (DM) in Mamelodi. Furthermore, it assesses what their purported medications comprise of.

Worldwide, obesity is a public health concern and a metabolic ailment characterized by excessive adipose tissue accumulation resulting from an imbalance of energy expenditure and energy intake [1]. This disorder is a known risk factor for cardiovascular disease, type 2 diabetes mellitus, dyslipidemia, hypertension, and metabolic

Background: The precise role of corticosteroids for treatment of coronavirus disease 2019 (COVID-19) is unclear due to lack of randomized trials. Objective: To review the therapeutic value of corticosteroids for treatment of hospitalized patients with COVID-19 with more emphasis on randomized trials. Methods: English literature search of electronic databases supplemented by manual search up to June 29, 2020. Search terms included corticosteroids, COVID-19, dexamethasone, methylprednisolone, hydrocortisone, mortality, safety. Randomized trials were the main focus of research, but observational studies were also reviewed.

Since December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused by 2019 Novel Coronavirus (2019-nCoV) has resulted in 89,000 cases of Corona Virus Disease 2019 (COVID-19), formerly known as Novel Coronavirus Pneumonia (NCP) in China, including 2,450 deaths.

Chronic hypertension is present in 1-2% of pregnant women. Women with chronic hypertension are at an increased risk of maternal and perinatal complications when compared with normotensive women. It is not uncommon for the women with chronic hypertension to present first time during pregnancy and obstetricians are the first one to encounter them during antenatal checkup. Secondary hypertension is often unrecognised and misdiagnosed thus leading to improper treatment with significant risk to the mother and fetus. 

Obesity has reached a global epidemic and it predisposes to the development of insulin resistance, type 2 diabetes and related metabolic diseases. Current interventions against obesity and/or type 2 diabetes such as calorie restriction, exercise, genetic manipulations or established pharmacological treatments have not been successful for many patients with obesity and/or type 2 diabetes.

Women with rare bleeding disorders (RBDs) can be exposed throughout their life to several complications such as menorrhagia or hemorrhagic complications during pregnancies and deliveries. Among RBDs, factor XIII deficiency leads to life-threatening hemorrhages such as intracranial hemorrhage, and women during their reproductive period may experience gynecological and obstetric complications, and more specifically recurrent miscarriages due to the role of FXIII in placenta attachment.

Prevalence of diabetes is increasing. Diabetes is more prevalent in the socially deprived, ethnic minority population (based on continuing rise in elderly population, growing obesity and BME groups). Compliance is a major stumbling block in the management of most long-term conditions including diabetes.

COVID-19 is the new emerging viral infection that already cause global public health problem. More than 220 countries/territories are already attacked and there are more than 17 million patients around the world. This disease was firstly reported in China then in Indochina and extended worldwide. The patient can have febrile respiratory illness and there are many asymptomatic and mild symptomatic cases. The new viral respiratory infection causes several medical and non-medical problems and it is a big challenge to be managed.